NMD670 — catalyst calendar
Upcoming
| Date | Event | Company | Drug | Official source & verification |
|---|---|---|---|---|
| 2026-12 (month) in 2mo
ESTIMATED |
READOUT
Safety and Efficacy of 3 Dose Levels of NMD670 in Adult Patients With Myasthenia
Phase 2 · Myasthenia Gravis, Myasthenia Gravis, MuSK |
NMD Pharma A/S | NMD670 |
ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
|